GB202309695D0 - Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups - Google Patents
Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroupsInfo
- Publication number
- GB202309695D0 GB202309695D0 GBGB2309695.1A GB202309695A GB202309695D0 GB 202309695 D0 GB202309695 D0 GB 202309695D0 GB 202309695 A GB202309695 A GB 202309695A GB 202309695 D0 GB202309695 D0 GB 202309695D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- patient subgroups
- cancer patient
- specific cancer
- novel
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2309695.1A GB2631308A (en) | 2023-06-27 | 2023-06-27 | Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups |
PCT/GB2024/051658 WO2025003680A1 (en) | 2023-06-27 | 2024-06-27 | Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2309695.1A GB2631308A (en) | 2023-06-27 | 2023-06-27 | Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups |
Publications (2)
Publication Number | Publication Date |
---|---|
GB202309695D0 true GB202309695D0 (en) | 2023-08-09 |
GB2631308A GB2631308A (en) | 2025-01-01 |
Family
ID=87517611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB2309695.1A Pending GB2631308A (en) | 2023-06-27 | 2023-06-27 | Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2631308A (en) |
WO (1) | WO2025003680A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8729048B2 (en) | 2011-11-22 | 2014-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents |
WO2014205105A1 (en) | 2013-06-19 | 2014-12-24 | The Regents Of The University Of California | Biomarkers of response to inhibition of poly-adp ribose polymerase (parp) in cancer |
WO2021050937A1 (en) * | 2019-09-12 | 2021-03-18 | The Wistar Institute Of Anatomy And Biology | Methods for the treatment of arid1a-deficient cancers |
WO2022051491A1 (en) * | 2020-09-02 | 2022-03-10 | Senhwa Biosciences, Inc. | Pharmaceutical compositions of tetracyclic quinolone analogs and their salts |
WO2022125470A1 (en) * | 2020-12-07 | 2022-06-16 | Foundation Medicine, Inc. | Comprehensive genomic profiling (cgp) of metastatic invasive lobular carcinomas reveals heterogeneity |
US20240269144A1 (en) * | 2021-06-02 | 2024-08-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods and kits for the detection of malignancies |
-
2023
- 2023-06-27 GB GB2309695.1A patent/GB2631308A/en active Pending
-
2024
- 2024-06-27 WO PCT/GB2024/051658 patent/WO2025003680A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2025003680A1 (en) | 2025-01-02 |
GB2631308A (en) | 2025-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287643A (en) | Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy | |
IL299167A (en) | Compositions and methods for treatment of gene therapy patients | |
PL3797741T3 (en) | Portable thermal therapy and support apparatus for emergency medical treatment | |
IL289787A (en) | Antibody combinations for treatment of cancer in specific patients | |
IL307964A (en) | Combination therapy for cancer treatment | |
IL299339A (en) | Antibodies and methods for treating claudin-associated diseases | |
GB202018015D0 (en) | Composition and methods for the treatment of intestinal cancer | |
GB202006072D0 (en) | Method of selecting patients for treatment with cmbination therapy | |
GB202309695D0 (en) | Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups | |
GB2594489B (en) | Patient positioning for radiotherapy treatment | |
GB202016173D0 (en) | Demethylation apparatus and cancer therapy apparatus comprising same, and demethylation method and aparatus for cancer therapy using same | |
GB202102026D0 (en) | Medical apparatus and method | |
EP4082577A4 (en) | Cancer treatment method and medicine | |
EP4284519A4 (en) | Methods for treating and ameliorating cancer | |
EP4130024A4 (en) | Method for predicting efficacy of treatment of lung cancer patient using immune checkpoint inhibitor | |
EP4134098A4 (en) | Method of cancer therapy | |
EP4190911A4 (en) | Method and drug for tumor treatment | |
IL317115A (en) | Methods for identifying and treating diseases | |
GB202010820D0 (en) | Patient repositioning apparatus and method | |
GB202102530D0 (en) | Method of selecting patients for treatment with combination therapy | |
GB202302196D0 (en) | Medical apparatus and method | |
GB202202014D0 (en) | Medical apparatus and method | |
CA235353S (en) | Medical treatment apparatus | |
PT4117667T (en) | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy | |
IL311229A (en) | Triple-agent therapy for cancer treatment |